Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332:609 (11 March), doi:10.1136/bmj.332.7541.609-a
| The first 150 words of the full text of this article appear below. |
EDITORWe agree with Balen et al that lifestyle modification, including effective exercise regimens and dietary advice, should be the first line of treatment in women with polycystic ovary syndrome.1 Our Cochrane review has been widely cited as supporting the use of metformin in women with this syndrome, but like Balen et al we too concluded that metformin should be used as an adjuvant to general lifestyle improvements and not as a replacement for them.2 An update of the Cochrane review should be available this year.
The complications of obesity both in infertility treatment and in subsequent pregnancy are well known.3 However, lifestyle modifications can bring about beneficial metabolic changes despite only modest reductions in weight, and body mass index (BMI) may not be a sensitive enough measure to detect clinically significant changes in metabolic parameters, with waist circumference being a better marker in women.4 More research is needed
Jonathan M Lord, consultant in obstetrics and gynaecology
Royal Cornwall Hospital, Truro, Cornwall TR1 3LJ jonathan.lord@pms.ac.uk
Robert Norman, professor
Research Centre for Reproductive Health, Discipline of Obstetrics and Gynaecology, University of Adelaide, Queen Elizabeth Hospital, 28 Woodville Road, Woodville, SA 5011, Australia